| Literature DB >> 30155451 |
David Kara1, Anna Hüsing-Kabar1, Hartmut Schmidt1, Inga Grünewald2, Gursimran Chandhok1,3, Miriam Maschmeier1, Iyad Kabar1.
Abstract
Background: Portal hypertension is a serious complication of liver cirrhosis. Objective: To identify relevant endoscopic findings in patients with advanced cirrhosis and consecutive portal hypertension.Entities:
Mesh:
Year: 2018 PMID: 30155451 PMCID: PMC6093009 DOI: 10.1155/2018/2182784
Source DB: PubMed Journal: Can J Gastroenterol Hepatol ISSN: 2291-2789
Demographic data and clinical and laboratory characteristics.
| n = 407 | |
| Age [years], median (range) | 60 (21–88) |
| Females/males, n (%) | 127 (31.2%)/280 (68.8%) |
| Ethanol (active or past substantial consumption) | 111 (27.3%) |
| Hepatitis C | 77 (18.9%) |
| Non-alcoholic fatty liver disease | 63 (15.4%) |
| Cryptogenic | 40 (9.8%) |
| Hepatitis B | 23 (5.7%) |
| Primary sclerosing cholangitis | 21 (5.2%) |
| Autoimmune hepatitis | 15 (3.7%) |
| Hemochromatosis | 9 (2.2%) |
| Wilson's disease | 7 (1.7%) |
| Primary biliary cirrhosis | 5 (1.2%) |
| Miscellaneous | 36 (8.8%) |
| Splenomegaly | 328 (82.8%) |
| Ascites | 228 (56.4%) |
| Encephalopathy | 118 (29.0%) |
| I–II | 103 (25.3% of all patients) |
| III–IV | 15 (3.7% of all patients) |
| Thrombocyte count | 101 (18–630) thousand/ |
| International normalized ratio | 1.3 (0.86–4.80) |
| Creatinine | 1 (0.10–16.60) mg/dL |
| Albumin | 3.3 (0.20–4.80) g/dL |
| Bilirubin | 3.9 (0.2–40.1) mg/dL |
| Child-Pugh score | |
| ≤ 6 | 142 (34.9%) |
| > 6 | 265 (65.1%) |
| Child-Pugh class | |
| A | 142 (34.9%) |
| B | 158 (38.8%) |
| C | 107 (26.3%) |
| Model for End Stage Liver Disease score, mean ± SD/ median (range) | 15.2 ± 7.3/ 13 (6–40) |
| Portal vein thrombosis | 35 (8.6%) |
| Hepatocellular carcinoma | 78 (19.2%) |
| Beta-blocker | 299 (73.5%) |
| Proton-pump inhibitor | 378 (92.9%) |
Endoscopic findings.
|
| n = 407 |
| Esophageal varices | 373 (91.6%) |
| Grade I | 145 (38.9%) |
| Grade II | 137 (36.7%) |
| Grade III | 91 (24.4%) |
| Barrett‘s esophagus | 28 (6,9%) |
| Gastric varices | 40 (9.8%) |
| Portal hypertensive gastropathy | 373 (91.6%) |
| Gastric polyps | 38 (9.5%) |
| Histopathology of endoscopically obtained biopsies (n = 36) | |
| Hyperplastic | 29 (80.6%) |
| Foveolar hyperplasia | 3 (8.3%) |
| Tubular adenoma | 1 (2.8%) |
| Inflammatory | 3 (8.3%) |
|
| 23 (10.5%) (n = 219) |
| Duodenal polyps | 32 (7.9%) |
| Histopathology of endoscopically obtained biopsies (n = 22) | |
| Hyperplastic | 10 (45.5%) |
| Tubular adenoma | 2 (9.1%) |
| Inflammatory | 1 (4.5%) |
| Brunner glands | 4 (18.2%) |
| Lipoma | 2 (9.1%) |
| Endocrine tumor | 2 (9.1%) |
| LGIEN | 1 (4.5%) |
|
| n = 363 |
| Colon polyps | 135 (37.2%) |
| Histopathology of endoscopically obtained biopsies (n = 113) | |
| Hyperplastic | 34 (30.1%) |
| Hyperplastic and LGIEN | 16 (14.2%) |
| LGIEN | 55 (48.7%) |
| Sessile adenoma | 2 (1.8%) |
| Adenocarcinoma | 4 (3.5%) |
| Leiomyoma | 2 (1.8%) |
Only tested in 219 patients.
LGIEN = low grade intraepithelial neoplasia.
Figure 1Chronological evolution of a portal hypertensive polyp in one patient after rubber band ligation of esophageal varices between 2014 and 2017 (a-f).
Figure 2Distribution of gastric polyps with regard to MELD score. Higher MELD score was associated with the presence of hypertensive polyposis of the stomach, suggesting a higher prevalence of gastric polyps in advanced cirrhosis. MELD: Model for End Stage Liver Disease.
Figure 3Bar chart showing the distribution of portal hypertensive polyposis with regard to rubber band ligation.
Figure 4Images of hypertensive polyps. (a) Macroscopic aspect of a portal hypertensive antral polyp. (b) Histological image of a hypertensive gastric polyp showing proliferating ectatic vessels (starlets).